I would say no. That is to say, there are parallel dynamics here.
First are the various avenues the Canadian government has and the Canadian people have to provide support to people to access drugs. CIDA has funding. We provide funding to support programs of WHO. We provide funding to support various other multilateral channels.
Then the question is how much people are paying for the drugs that are being delivered through those channels. These intersect in terms of their consequence, but they're two different dynamics. What CAMR is doing is affecting the price people are paying for drugs produced in Canada. And because it isn't working, Canadian suppliers are only supplying high-cost drugs to those systems, and as a consequence, they aren't the producers of choice, because there are other countries--Brazil and India, in particular, but others--that are actually meeting the need.
So if you had a million dollars of aid money to spend on drugs, you would not go to one of the brand name drug manufacturers to buy those things. Right? And that's the situation we are in. It isn't that they're completely unrelated, but CAMR is not about avenues for delivering drugs or the effectiveness of delivering drugs; it's about how much we're spending in order to access those drugs.